Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients
Recommended
Calviri Scientists Find New Class of Biomarkers for Predicting Treatment Response in Cancer Patients
Scientists studying various immune checkpoint inhibitor therapies in patients with advanced lung cancer have found that a new class of blood-based biomarkers— anti-frameshift peptide antibodies, or anti-FSP antibodies— could be developed into improved or orthogonal tests for predicting tumor responses to treatment.
Access the full article to read more here.
<!-- BEGIN ADVERTSERVE CODE -->
<div id="mobile_block_ad_1"><script type="text/javascript">
var _avp = _avp || [];
_avp.push({ tagid: 'mobile_block_ad_1', alias: '/', type: 'banner', zid: 1669, pid: 0, onscroll: 0, inview: true, secure: true });
</script></div>
<!-- END ADVERTSERVE CODE -->